Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Lilly’s Taltz meets endpoints in Phase III study for nr-axSpA

pharmaceutical-technologyApril 24, 2019

Tag: Drug , Taltz , nr-axSpA , COAST-X

PharmaSources Customer Service